Explore every episode of the podcast Decera Clinical Education Oncology Podcast

Dive into the complete episode list for Decera Clinical Education Oncology Podcast. Each episode is cataloged with detailed descriptions, making it easy to find and explore specific topics. Keep track of all episodes from your favorite podcast and never miss a moment of insightful content.

	Title	Pub. Date	Duration
	PARP Inhibitors in Metastatic Prostate Cancer: Biomarker Testing, Treatment Strategies, and Toxicity Management	09 Oct 2026	00:27:13
In this podcast episode, Neeraj Agarwal, MD, FASCO, and Emmanuel S. Antonarakis, MD, discuss the evolving role of PARP inhibitors in metastatic prostate cancer, emphasizing early molecular testing to identify appropriate patients for PARP-directed therapy and proactive adverse event management to support treatment continuation, including: HRR alterations and the mechanism of action of PARP inhibitors Germline and somatic genomic testing and practical considerations for tissue and ctDNA testing PARP inhibitor monotherapy and combination strategies, including data from AMPLITUDE and TALAPRO-3 Treatment selection across metastatic prostate cancer settings based on HRR alterations PARP inhibitor toxicity management, with emphasis on anemia, gastrointestinal effects, monitoring, and dose modification Presenters: Neeraj Agarwal, MD, FASCO Medical Oncologist, Dana-Farber Cancer Institute Co-Director, Prostate Cancer Program, Harvard Cancer Consortium The Lank Center for Genitourinary Oncology Boston, Massachusetts Emmanuel S. Antonarakis, MD Clark Endowed Professor of Medicine Director of GU Oncology, Associate Director of Translation Division of Hematology, Oncology and Transplantation University of Minnesota, Masonic Cancer Center Minneapolis, Minnesota Link to full program: https://bit.ly/4dtT35U Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Experts Discuss Sequencing of Therapies for Relapsed/Refractory Multiple Myeloma	30 Sep 2026	00:28:40
Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates (ADCs), bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma. Presenters: Jesus G. Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research Partner Tennessee Oncology Nashville, Tennessee Ajai Chari, MD Professor of Clinical Medicine Director of Multiple Myeloma Program UCSF Helen Diller Family Comprehensive Cancer Center University of California, San Francisco (UCSF) Medical Center San Francisco, California Content based on an online CME program supported by an educational grant from GSK. Link to full program: https://bit.ly/3TZSmuf Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	ASCO 2026 Updates in Metastatic Breast Cancer	22 Sep 2026	00:18:43
In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with metastatic breast cancer, including: Findings from SERENA-6 on ctDNA-guided treatment switching for emergent ESR1 mutations before radiographic progression, including updated PFS2 and downstream treatment outcomes Emerging precision strategies in HR-positive/HER2-negative advanced breast cancer from ELEVATE and PIKALO-1, including elacestrant plus capivasertib and mutant-selective PI3Kα inhibition with tersolisib First-line TROP2-directed ADC data from ASCENT-04, ASCENT-03, and TROPION-Breast02, with discussion of PFS2, subsequent therapy, immunotherapy eligibility, and treatment sequencing Presenters: Hope S. Rugo, MD, FASCO Director, Women’s Cancer Program Division Chief, Breast Medical Oncology Professor, Department of Medical Oncology & Therapeutics Research City of Hope Comprehensive Cancer Center Professor Emeritus and Emeritus Winterhof Family Distinguished Professor of Breast Oncology University of California, San Francisco San Francisco, California Nerea Lopetegui-Lia, MD Assistant Professor Division of Medical Oncology, Breast Section Department of Internal Medicine The Ohio State University Columbus, Ohio Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Link to full program: https://bit.ly/4x4u5AT Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape	10 Sep 2026	00:35:21
In this podcast episode, Charles Rudin, MD, PhD, and Mark A. Socinski, MD, discuss current gaps and clinical needs for patients with relapsed ES-SCLC, and the evolving role of B7-H3–directed antibody–drug conjugates in the management of patients with ES-SCLC, including: Clinical needs for relapsed ES-SCLC Scientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLC ADCs, T-cell engagers, chemotherapy-based approaches, maintenance strategies, and ongoing clinical trials for ES-SCLC Recent efficacy and safety data for B7-H3–directed ADCs in ES-SCLC, including I-DXd Personalization of care of patients with SCLC, including patient-specific factors influencing treatment Case discussion of a patient with ES-SCLC requiring optimal next best treatment Importance of enrolling patients in ongoing trials of investigational agents for patients with ES-SCLC Presenters: Charles Rudin, MD, PhD Cancer Center Director Memorial Sloan Kettering Cancer Center New York, New York Mark A. Socinski, MD Executive Medical Director AdventHealth Cancer Institute Orlando, Florida Link to full program: https://bit.ly/3UBEeYz Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing	04 Sep 2026	00:29:16
In this podcast episode, BJ Rimel, MD, and Elizabeth Lee, MD, discuss the scientific rationale for targeting CDH6 in ovarian cancer and the emerging role of CDH6-directed antibody–drug conjugates (ADCs) in platinum-resistant disease, including: CDH6 biology, expression patterns, and its potential as a therapeutic target in ovarian cancer Early-phase efficacy data with investigational CDH6-directed ADCs, including raludotatug deruxtecan (R-DXd) and CUSP06, and an ongoing phase III trial of R-DXd Safety considerations with CDH6-directed ADCs, including cytopenias, gastrointestinal toxicities, fatigue, and interstitial lung disease/pneumonitis Considerations for sequencing ADCs, including the potential impact of target expression, payload class, and mechanisms of resistance Presenters: BJ Rimel, MD Division Chief, Gynecologic Oncology Professor, Department of OB/GYN University of Washington Clinical Director of Gynecologic Oncology Fred Hutchinson Cancer Center Seattle, Washington Elizabeth Lee, MD Division of Gynecologic Oncology Center for Cancer Therapeutic Innovation Department of Medical Oncology Dana-Farber Cancer Institute Boston, Massachusetts Link to full program: https://bit.ly/3SqCAZ6 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer	04 Sep 2026	00:09:10
In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with early-stage hormone receptor (HR)–positive/HER2-negative breast cancer, including: Findings from the OPTIMA trial evaluating Prosigna gene expression testing to guide adjuvant chemotherapy decisions in patients with high-risk HR-positive/HER2-negative early breast cancer The importance of ovarian function suppression plus endocrine therapy when considering chemotherapy-sparing strategies in premenopausal patients Results from the NATALEE PAM50 biomarker analysis, showing ribociclib benefit across intrinsic subtypes with no significant treatment-by-subtype interaction Presenters: Hope S. Rugo, MD, FASCO Director, Women’s Cancer Program Division Chief, Breast Medical Oncology Professor, Department of Medical Oncology & Therapeutics Research City of Hope Comprehensive Cancer Center Professor Emeritus and Emeritus Winterhof Family Distinguished Professor of Breast Oncology University of California, San Francisco San Francisco, California Nerea Lopetegui-Lia, MD Assistant Professor Division of Medical Oncology, Breast Section Department of Internal Medicine The Ohio State University Columbus, Ohio Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Link to full program: https://bit.ly/4x4u5AT Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	CELMoDs on the Horizon: A New Chapter in Lymphoma Care	24 Aug 2026	00:22:30
Treatment options for patients with lymphoma are rapidly evolving. In this podcast episode, Alex F. Herrera, MD, and Marc Hoffmann, MD, discuss cereblon E3 ligase modulators (CELMoDs) as potential treatment options for patients with aggressive diffuse large B-cell lymphoma and follicular lymphoma, with a focus on golcadomide, an investigational, oral, first-in-class CELMoD therapy. Topic areas covered include: Biologic and clinical rationale for the use of CELMoD therapy in lymphoma patients Emerging clinical trial data on golcadomide alone and in combination with other regimens Real-world expectations for incorporating CELMoD-based therapies into community lymphoma care settings such as efficacy, patient selection, and toxicity management strategies Presenters: Alex F. Herrera, MD Chief, Division of Lymphoma Professor, Department of Hematology and Hematopoietic Cell Transplantation Director, Toni Stephenson Lymphoma Center City of Hope Duarte, California Marc Hoffmann, MD Director, Lymphoma Program Medical Director, Lean and Quality Improvement Associate Professor Division of Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center Kansas City, Kansas Content based on an online CME program supported by an educational grant from Bristol Myers Squibb. Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Link to CME: Claim Credit Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Experts Discuss Health Disparities and Equitable Care Strategies in Multiple Myeloma	20 Aug 2026	00:13:51
In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss health disparities and equitable care strategies in multiple myeloma, including: Treatment for underserved populations Navigating REMS for novel therapeutics Clinical trial design and enrolment Presenters: Jesus G. Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research Partner Tennessee Oncology Nashville, Tennessee Ajai Chari, MD Professor of Clinical Medicine Director of Multiple Myeloma Program UCSF Helen Diller Family Comprehensive Cancer Center University of California, San Francisco (UCSF) Medical Center San Francisco, California Content based on an online CME program supported by an educational grant from GSK. Link to full program: https://bit.ly/3TZSmuf Get access to all of our new podcasts by subscribing tothe Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Experts Discuss CELMoD Agents for Multiple Myeloma	20 Aug 2026	00:26:03
In this podcast episode, Meletios-Athanasios (Thanos) C. Dimopoulos, MD, and María-Victoria Mateos, MD, PhD, as they discuss the use of CELMoD agents to manage multiple myeloma, including: The recent FDA approval of iberdomide Mechanism of action and differentiation from IMiDs Current data and potential treatment settings Presenters: Meletios-Athanasios (Thanos) C. Dimopoulos, MD Professor and Chairman Plasma Cell Dyscrasias Unit Section of Hematology and Medical Oncology Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Alexandra Hospital Athens, Greece María-Victoria Mateos, MD, PhD Myeloma Unit, Director Professor of Medicine University Hospital of Salamanca Salamanca, Spain Content based on an online CME program supported by an educational grant from Bristol Myers Squibb. Link to full program: https://bit.ly/4xgnHri Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Optimizing Oral Targeted Therapies for HR+/HER2- Breast Cancer	14 Aug 2026	00:32:42
In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection across early-stage and metastatic disease, biomarker-informed decision-making, adverse event management, and practical strategies to help patients remain on therapy. Key topics include: Selecting and sequencing oral targeted therapies, including CDK4/6 inhibitors, PARP inhibitors, PI3K/AKT pathway inhibitors, and oral SERDs Identifying patients with high-risk early breast cancer and applying evidence from trials such as monarchE, NATALEE, and OlympiA Using biomarkers such as BRCA1/2, PIK3CA, AKT1, PTEN, and ESR1 to guide therapy in metastatic disease Monitoring and managing treatment-related adverse events, including neutropenia, diarrhea, hepatotoxicity, QTc prolongation, hyperglycemia, rash, stomatitis, anemia, nausea, and fatigue Using dose modification, supportive care, patient education, and proactive follow-up to improve adherence and persistence with oral therapy Incorporating oncology pharmacists and the multidisciplinary care team into ongoing treatment monitoring and patient support Presenters Danielle Roman, PharmD, BCOP Manager, Oncology Clinical Pharmacy Services Oncology Clinical Pharmacy Specialist Allegheny Health Network Pittsburgh, Pennsylvania Jordan Hill, PharmD, BCOP Clinical Pharmacy Specialist, Breast Oncology West Virginia University Cancer Institute Morgantown, West Virginia Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Access the full educational program: Link to full program: https://bit.ly/4gvZerW And be sure to try our Interactive Decision Support Tools for Early Breast Cancer and Selecting AKT or PI3K Inhibitors for Patients With Metastatic Breast Cancer. By answering just a few quick questions, you can see what 5 experts would recommend for specific patient scenarios. Early Breast Cancer: https://bit.ly/4gtUiUq AKT or PI3K Inhibitors in MBC: https://bit.ly/4qcyBvk Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	TGCT Today: Understanding Diagnosis, Treatment, and Long-term Care	13 Aug 2026	00:36:17
Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive disease that can cause chronic pain, joint dysfunction, reduced mobility, and significant impacts on quality of life, particularly in patients with diffuse disease. In this expert discussion, Dr William Tap and Dr Emanuela Palmerini explore the evolving management of TGCT, including the biologic role of the CSF1/CSF1R pathway, challenges in diagnosis and disease monitoring, and the importance of multidisciplinary, patient-centered care. They also discuss the growing role of CSF1R-targeted therapies, treatment selection, toxicity management, drug holidays, and practical approaches to optimizing long-term outcomes for patients living with TGCT. Topics Covered Understanding localized vs diffuse TGCT Biology of the CSF1/CSF1R pathway Diagnostic approaches and the role of MRI and biopsy Multidisciplinary care and shared decision-making Impact of TGCT on function, mobility, and quality of life Current and emerging CSF1R-targeted therapies Pexidartinib and vimseltinib: clinical considerations and toxicity management Response assessment beyond imaging Drug holidays, retreatment strategies, and long-term follow-up Future directions in TGCT research and treatment Faculty William Tap, MD Emanuela Palmerini, MD, PhD Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives	12 Aug 2026	00:28:57
In this podcast episode, James A. Davis, PharmD, BCOP, and Kelley L. Julian, PharmD, BCOP, discuss evidence-based strategies for managing smoldering and newly diagnosed multiple myeloma, including: Risk stratification and treatment selection for smoldering multiple myeloma Anti-CD38–based regimens for transplant-eligible and transplant-ineligible patients Clinical evidence supporting triplet and quadruplet therapies MRD assessment and response-adapted treatment strategies Frailty, transplant eligibility, and individualized treatment selection Subcutaneous anti-CD38 administration and premedication requirements Pharmacist-led supportive care, toxicity management, dose modification, and patient counseling Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: James A. Davis, PharmD, BCOP Clinical Pharmacy Specialist, Myeloma/Lymphoma The Medical University of South Carolina, Hollings Cancer Center Affiliate Assistant Professor MUSC College of Pharmacy Charleston, South Carolina Kelley L. Julian, PharmD, BCOP Hematology/BMT Pharmacy Supervisor PGY2 Oncology Pharmacy Residency Program Director Huntsman Cancer Institute, University of Utah Salt Lake City, Utah Link to full program: https://bit.ly/4qaRb7n Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	New and Emerging Targeted Therapies for Patients With DLBCL	07 Aug 2026	00:38:55
In this podcast episode, Gilles Salles, MD, PhD, and Pier Luigi Zinzani, MD, PhD, discuss the role of new and emerging targeted therapies in the management of patients with DLBCL, including: Overview of Unmet Needs With Current Standard of Care in DLBCL Expanding Role of Novel Agents in DLBCL Access to Targeted Therapies and Clinical Trials in Non-Academic DLBCL Practice Key Ongoing Trials of new and novel agents in DLBCL Key Presentations/Results at EHA 2026 in DLBCL Presenters: Gilles Salles, MD, PhD Service Chief, Lymphoma Service Steven Greenberg Chair Memorial Sloan Kettering Cancer Center Weill Cornell University New York, New York Pier Luigi Zinzani, MD, PhD Professor of Hematology Alma Mater Studiorum-University of Bologna Head, “Seràgnoli” Institute of Hematology IRCCS Azienda Ospedaliero-Universitaria di Bologna Department of Medical and Surgical Sciences Bologna University School of Medicine Bologna, Italy Link to full program: https://bit.ly/4gmyoS7 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Changing the Paradigm in HER2-Positive Early Breast Cancer	07 Aug 2026	00:25:04
New data and broad indications for trastuzumab deruxtecan are changing the paradigm for HER2-positive early breast cancer. Listen to Shanu Modi, MD, and Sara A. Hurvitz, MD, FACP, discuss how they are incorporating these changes into clinical practice in the neoadjuvant, adjuvant, and possibly metastatic settings. Presenters: Sara A. Hurvitz, MD, FACP Professor of Medicine Smith Family Endowed Chair in Women’s Health Senior Vice President, Clinical Research Division Fred Hutch Cancer Center Head, Division of Hematology/Oncology, Department of Medicine University of Washington School of Medicine Seattle, Washington Shanu Modi, MD Section Head, HER2 Breast Program Professor and Attending Member Breast Medicine Service, Department of Medicine Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York, New York Link to full program: https://bit.ly/4z1Xb6a Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Recent Advances, Future Directions, and Ideas on Integrating CELMoDs Into The Care Of Patients With Myeloma	03 Aug 2026	00:17:59
Listen in to learn from Sagar Lonial, MD, and Mohamad Mohty MD, PhD, about the advantages and future implications of the next-generation protein degradation modulator based therapy and find out how to integrate their use into your practice. Presenters: Sagar Lonial, MD, FACP, FASCO Chair and Professor Department of Hematology and Medical Oncology Anne and Bernard Gray Family Chair in Cancer Chief Medical Officer Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia Mohamad Mohty, MD, PhD Sorbonne University Paris, France Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	To Treat or Not to Treat: Assessing Risk and Treatment Options in High-Risk SMM	29 Jul 2026	00:48:21
In this podcast episode, Natalie S. Callander, MD, and Tom Martin, MD, discuss the optimal approaches for the determination of whether a patient with high-risk SMM requires treatment or observation, including: Contemporary Risk Stratification Interpreting Evidence for Early Intervention Treatment vs Observation: Patient Selection Treatment Selection and Sequencing Considerations Safety, Monitoring, and Supportive Care Implementation in Practice Shared Decision-making and Patient Communication Emerging Therapies and Clinical Trials Presenters: Natalie S. Callander, MD Professor of Medicine Director, Myeloma Clinical and Cellular Therapy Program University of Wisconsin Carbone Cancer Center Madison, Wisconsin Tom Martin, MD Professor of Medicine Associate Chief, Hematology/Oncology UCSF Medical Center San Francisco, California Link to full program: https://bit.ly/4wqpYzU Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Unmet Needs, Recent Advances, and Expert Insights on Integrating TROP-2 ADCs Into the Care of Patients With TNBC	28 Jul 2026	00:22:12
Listen in to learn from Thomas Bachelot, MD, PhD, and Mafalda Oliveira, MD, PhD, about recent advances and the integration of anti-TROP2 antibody-drug conjugates (ADCs) into the management of patients with triple-negative breast cancer, including as first-line therapy for those who are not eligible for immunotherapy. Experts will cover: The evolving role of TROP2-directed antibody-drug conjugates (ADCs), including sacituzumab govitecan and datopotamab deruxtecan, in addressing unmet needs in the frontline treatment of TNBC. Treatment sequencing, reimbursement barriers to recent approvals, and toxicity-informed treatment selection considerations. How to monitor and manage ocular and pulmonary toxicities and care-team readiness for implementing ADC-based therapy in routine practice. Presenters: Thomas Bachelot, MD, PhD Medical Oncology Department of Oncology Léon Bérard Center Lyon, France Mafalda Oliveira, MD, PhD Senior Consultant Medical Oncology Department Vall d’Hebron University Hospital Senior Clinical Investigator Breast Cancer Group Vall d’Hebron Institute of Oncology (VHIO) Vall d’Hebron Barcelona Hospital Campus Barcelona, Spain Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Optimizing Bispecific Antibody Safety and Care Coordination From the Pharmacy in RRMM	23 Jul 2026	00:30:58
In this episode, Dr Sara Ann Scott and Dr Syeda Saba Kareem discuss toxicities and the safe management of bispecific antibodies used in the treatment of RRMM to improve outcomes for patients, including: The incidence of cytokine release syndrome (CRS), along with the grading system, treatment strategies, and the role of tocilizumab Neurologic toxicities like the clinical manifestation of ICANS and the ICE scoring system used to help assign grading and appropriate treatment with dexamethasone, levetiracetam, and/or high-dose methylprednisolone Infection susceptibilities associated with BCMA-targeted bispecific antibodies and how this varies for GPRC5D-directed targets throughout therapy How to set up and maintain a REMS program Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Syeda Saba Kareem, PharmD, BCOP Clinical Pharmacy Supervisor Malignant Hematology Moffitt Cancer Center Tampa, Florida Sara A. Scott, PharmD, BCOP Clinical Pharmacy Specialist, Multiple Myeloma Emory Winship Cancer Institute Atlanta, Georgia Link to full program: https://bit.ly/3RUyrMx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies	22 Jul 2026	00:28:50
In this episode, Dr Paul E. Oberstein, Dr Andrew H. Ko, and Dr Efrat Dotan discuss recent advances in pancreatic cancer, including: The evolving role of chemotherapy Utility of tumor treating fields for the treatment of locally advanced pancreatic adenocarcinoma Emerging RAS-targeted strategies and novel approaches for CLDN18.2- and MTAP-altered disease The potential impact of these developments on future treatment sequencing and supportive care Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Paul E. Oberstein, MD, MS Section Chief, GI Oncology Associate Professor of Medicine Co-Director, KRAS Excellence Initiative Perlmutter Cancer Center NYU Langone Health New York, New York Andrew H. Ko, MD, FASCO Professor of Medicine and Associate Chief Division of Hematology/Oncology University of California San Francisco San Francisco, California Efrat Dotan, MD, MTR Clinical Professor of Medicine (Hematology/Oncology) Executive Medical Director, Penn Medicine, Ann B. Barshinger Cancer Center Penn Center for Cancer Care Innovation, Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania Link to full program: https://bit.ly/44HPR1U Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today	14 Jul 2026	00:26:54
Treatment options for patients with multiple myeloma are rapidly evolving. In this podcast episode, Jesus Berdeja, MD, and Amrita Krishnan, MD, FCAP, discuss GPRC5D-directed treatment options for patients with relapsed/refractory multiple myeloma, with a focus on talquetamab, a GPRC5D-directed bispecific antibody. Topic areas covered include: Clinical trial updates and discussion of how findings may translate into clinical practice and FDA approvals Treatment sequencing and patient selection Step-up dosing and what to expect in terms of toxicity management when using a GPRC5D-targeted therapy with on-target, off-tumor effects Presenters: Jesus Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research Partner Tennessee Oncology Nashville, Tennessee Amrita Krishnan, MD, FCAP Nason Hollingworth Family Chair in Myeloma Director, Judy and Bernard Briskin Center for Myeloma Professor Hematology/HCT Executive Director of Hematology City of Hope Orange County Irvine, California Content based on an online CME program supported by an educational grant from Johnson & Johnson. Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma	13 Jul 2026	00:28:33
In this podcast episode, Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, and Anthony Perissinotti, PharmD, BCOP, discuss the role, efficacy, and safety of agents targeting BCMA in the personalized care of patients with multiple myeloma after disease progression on 1 or 2 previous lines of therapy, including: A Brief Overview of BCMA in Multiple Myeloma Advances in BCMA-Targeted Agents in Progressing Myeloma Selection of BCMA-Directed Therapies for Early Relapse MM Operational Challenges Faced by Oncology Pharmacists Regarding the Incorporation of BCMA-Targeted Agents in Practice Identifying and Managing Adverse Events Associated With BCMA-Directed Agents Presenters: Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP Clinical Oncology Pharmacy Manager Atrium Health Levine Cancer Institute Charlotte, North Carolina Anthony Perissinotti, PharmD, BCOP Hematology Clinical Pharmacist Specialist University of Michigan Ann Arbor, Michigan Link to full program: https://bit.ly/4gCsgXt Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer	30 Jun 2026	00:24:04
Listen in to learn from Cristina Saura Manich, MD, PhD and Giampaolo Bianchini, MD about practical approaches to PI3K pathway testing, PI3K/AKT-targeted treatment options, and endocrine-based sequencing in metastatic breast cancer. Presenters: Cristina Saura Manich, MD, PhD Head, Breast Cancer Unit Medical Oncology Service Vall d'Hebron University Hospital Breast Cancer Program, Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain Giampaolo Bianchini, MD Associate Professor, Universita Vita-Salute San Raffaele Head, Breast Cancer Group, Department of Medical Oncology Head, Clinical Translational and Immunotherapy Research IRCCS Ospedale San Raffaele Milan, Italy Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion. https://bit.ly/4p6W8gP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider	22 Jun 2026	00:26:58
Link to claim CME credit: https://bit.ly/4uRr3ir In this episode, Elizabeth Krueger, NP, and Sam Vafadar, DHSc, PA-C, discuss how they optimize first-line EGFR-targeted therapy for patients with EGFR-mutated NSCLC, including: First-line treatment options available for EGFR-mutated NSCLC and the clinical trials that resulted in their approval Adverse event identification and management Generalized strategies to support patient adherence to TKIs Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify Presenters: Elizabeth Krueger, NP Center for Thoracic Cancers Mass General Brigham Cancer Institute Boston, Massachusetts Sam Vafadar, DHSc, PA-C Physician Associate Department of Thoracic Oncology H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Advancing the Early Detection of Lung Cancer: Expanding Screening Access, Eligibility, and Awareness	09 Jun 2026	00:27:23
In this episode, Dr Abbie Begnaud discusses the importance of lung cancer screening and evolving strategies to improve early detection among high-risk populations, including: Low-dose CT screening, which reduces lung cancer mortality by detecting cancers at earlier, more treatable stages Updated screening guidelines that have expanded eligibility Key challenges that impact screening participation, including awareness, access, and broader risk assessment Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenter: Abbie Begnaud, MD, FCCP Associate Professor of Medicine University of Minnesota Pulmonary, Critical Care, Allergy and Sleep Medicine Program Director, Interventional Pulmonology Fellowship University of Minnesota Health Lung Cancer Screening Program Link to full program: Advancing the Early Detection of Lung Cancer: A Multipronged Educational Initiative to Elevate Evidence-Based Screening Practices \| Decera Clinical Education Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	HNSCC: Current and Emerging Therapeutic Strategies	29 May 2026	00:26:24
In this episode, Aarti Bhatia, MD, MPH, and Deborah J. Wong, MD, PhD, discuss the rapidly evolving treatment landscape for recurrent, metastatic, and locally advanced head and neck squamous cell carcinoma (HNSCC), including the growing role of immune checkpoint inhibitors, perioperative treatment strategies, EGFR-targeted bispecific antibodies, antibody–drug conjugates, HPV-targeted vaccines, and novel radiosensitizers. The discussion also explores emerging phase III clinical trials, treatment sequencing considerations, and future precision oncology approaches for HPV-positive and HPV-negative patients with head and neck cancer. Presenters: Aarti Bhatia, MD, MPH Associate Professor of Medicine (Medical Oncology) Clinical Research Team Leader, Head and Neck Cancers Program Yale Cancer Center New Haven, Connecticut Deborah J. Wong, MD, PhD Director, Head and Neck Medical Oncology Program Associate Clinical Professor of Medicine Division of Hematology/Oncology University of California, Los Angeles (UCLA) Los Angeles, California Link to full program: https://bit.ly/49kViqg Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies	15 May 2026	00:20:50
In this episode, hear Doris K. Hansen, MD, discuss the management of relapsed/refractory multiple myeloma with bispecific antibodies including: Practical differences among approved bispecific antibodies Toxicity profiles of approved bispecific antibodies When to refer patients for evaluation for immunotherapies Considerations for sequencing bispecific antibodies in the relapsed/refractory setting New findings with combination regimens with bispecific antibodies Program faculty: Doris K. Hansen, MD Assistant Member, Blood and Marrow Transplant and Cellular Immunotherapy H. Lee Moffitt Cancer Center & Research Institute Assistant Professor University of South Florida Morsani College of Medicine Tampa, Florida Link to program page: https://bit.ly/4nufxr2 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma	07 May 2026	00:31:00
In this episode, Muhamed Baljevic, MD, FACP, and Johnathan Ticku, MD, discuss various strategies to optimize the use of bispecific antibodies in their practices for the treatment of R/R MM through patient monitoring, dosing in outpatient settings, and using tocilizumab and IVIG, among other management strategies. Presenters: Muhamed Baljevic, MD, FACP Associate Professor of Medicine Division of Hematology-Oncology Department of Medicine Director, Multiple Myeloma Program Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP) Co-Chair, Scientific Review Committee, VICC Disease Team Lead, Plasma Cell Dyscrasias and Lymphomas Vanderbilt-Ingram Cancer Center Vanderbilt University Medical Center Nashville, Tennessee Jonathan Ticku, MD Medical Oncologist and Hematologist GU Oncology Lead, Mayo Clinic Health System Assistant Professor of Oncology, Mayo Clinic La Crosse, Wisconsin Link to full program: https://bit.ly/4u0xH6q Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Thrombotic Events and ET/PV: What You Should Know	30 Apr 2026	00:22:08
In this episode, hear Anthony Hunter, MD and Douglas Tremblay, MD discuss the various presentations of thrombotic events in patients with PV or ET including how thrombotic events may lead to diagnosis: PV and ET increase the risk of both arterial and venous thrombotic events Unusual thrombotic events Thrombosis as initial presentation for MPN Case presentations Brief overview of thrombosis management Program faculty: Anthony M. Hunter, MD Associate Professor, Department of Hematology and Medical Oncology Leader, Myeloproliferative Neoplasm Program Medical Director, Rollins Immediate Care Center Winship Cancer Institute of Emory University, Leukemia Group Atlanta, Georgia Douglas Tremblay, MD Associate Professor of Medicine Division of Hematology/Oncology Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York, New York Link to obtain CME/CE credit: https://bit.ly/4egx4Rf Link to program page: https://bit.ly/3OPSASy Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Global Experts Discuss Current and Emerging Treatments for ET and PV	30 Apr 2026	00:17:21
In this podcast episode, Ciro Rinaldi MD, PhD, and Alessandro M. Vannucchi, MD, discuss contemporary management of essential thrombocythemia (ET) and polycythemia vera (PV), as well as novel investigational approaches, including the following: Overview of current treatment paradigms for PV and ET Importance of shared decision-making and patient communication in determining treatment Current therapeutic areas of need in ET and PV Emerging investigational therapeutics Presenters: Ciro Rinaldi MD, PhD Chief Medical Officer, United Lincolnshire Teaching Hospital Honorary Professor of Haematology, University of Lincoln Honorary Professor De Montfort University Dubai Consultant Haematologist Lincoln, United Kingdom Alessandro M. Vannucchi, MD Professor of Hematology University of Florence Director of Hematology Department Director of Oncology Department Azienda Ospedaliera Universitaria Careggi Florence, Italy Content based on an online CME program supported by an educational grant from Merck. Link to full program: https://bit.ly/4u09lKd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Global Experts Discuss Diagnostic Considerations in ET and PV	29 Apr 2026	00:14:55
In this podcast episode, Ciro Rinaldi, MD, PhD, and Alessandro M. Vannucchi, MD, as they discuss contemporary topics in diagnosing essential thrombocythemia (ET) and polycythemia vera (PV), including: Overview of diagnostic criteria for PV and ET Importance of bone marrow biopsy Degree of suspicion of PV/ET in patients presenting with thrombotic events Pearls of wisdom in diagnosis Presenters: Ciro Rinaldi, MD, PhD Chief Medical Officer, United Lincolnshire Teaching Hospital Honorary Professor of Haematology, University of Lincoln Honorary Professor De Montfort University Dubai Consultant Haematologist Lincoln, United Kingdom Alessandro M. Vannucchi, MD Full Professor of Hematology University of Florence Director of Hematology Department Director of Oncology Department Azienda Ospedaliera Universitaria Careggi Florence, Italy Content based on an online CME program supported by an educational grant from Merck. Link to full program: https://bit.ly/4u09lKd Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Experts Discuss Novel Approaches to First-line Therapy for HER2-Positive Metastatic Breast Cancer	17 Apr 2026	00:22:41
In this podcast episode, Erika Hamilton, MD, FASCO, and Ian Krop, MD, PhD, discuss recent developments in the field of first-line therapy and maintenance treatment for patients with HER2-positive metastatic breast cancer, including the following: Trastuzumab deruxtecan plus pertuzumab as first-line therapy based on data from DESTINY-Breast09 Adding palbociclib to HP and ET as maintenance therapy for HR-positive/HER2-positive MBC, based on data from PATINA Adding tucatinib to HP as maintenance therapy for HER2-positive MBC, based on data from HER2CLIMB-05 Presenters: Erika Hamilton, MD, FASCO Chief Development Officer, Late Phase Director, Breast Cancer Research Program Sarah Cannon Research Institute (SCRI) Nashville, Tennessee Ian Krop, MD, PhD Professor of Medicine, Yale School of Medicine Associate Cancer Center Director for Clinical Research Yale Cancer Center New Haven, Connecticut Content based on an online CME program supported by an educational grant from Pfizer. Link to full program: https://bit.ly/4esvN9x Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Patient Voices: Caring for the Whole Patient and Personalizing Treatment of Early Breast Cancer to Achieve Equitable Outcomes	15 Apr 2026	00:41:42
A patient advocate/cancer survivor and a healthcare professional discuss key topics including early breast cancer diagnosis, role of self-agency in pursuing optimal cancer care, encouraging trial participation with patient testimonials, and other considerations for the patient care journey such as appropriate screening, follow-up encounters for questions, guideline-based treatments, and side effect management. Participants Kristen D. Whitaker, MD, MS Breast Medical Oncologist Medstar Georgetown Center Institute at Washington Hospital Center Assistant Professor of Medicine Georgetown University School of Medicine Washington, DC Asha Miller Founder, Asha Miller Creative Patient Advocate and Consultant Patient Experience and Health Equity Breast Cancer Veteran Columbus, Ohio Link to full program: https://bit.ly/47XIKV7 Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities	15 Apr 2026	00:31:22
Podcast with global experts discussing the role of AKT and PI3K inhibitors in patients with resistance to endocrine therapy in the adjuvant or metastatic disease settings following current guidelines, indications, and best clinical practices. Presenters: Nadia Harbeck, MD Breast Cancer Director Department of OB&GYN and Comprehensive Cancer Center Munich LMU University Hospital Munich, Germany Francois-Clement Bidard, MD, PhD Breast Medical Oncology Institut Curie & University of Versailles Paris, France Link to full program: https://bit.ly/4cFd0Xj Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Patient-Centered Management of CDK4/6 Inhibitor Therapy: Adverse Event Mitigation, Adherence, and Persistence in HR+/HER2- Breast Cancer	14 Apr 2026	00:44:46
In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss patient-centered management of CDK4/6 inhibitor therapy in HR-positive/HER2-negative breast cancer, with a focus on how oncology pharmacists and the multidisciplinary care team can support patients through treatment, including: Practical strategies for monitoring and managing key adverse events associated with abemaciclib, ribociclib, and palbociclib, such as diarrhea, neutropenia, hepatotoxicity, and QT prolongation How dose interruptions and dose reductions can help improve tolerability while maintaining clinical benefit Real-world approaches to patient education, toxicity counseling, and communication that can improve adherence and persistence with oral CDK4/6 inhibitor therapy Additional considerations such as financial toxicity, coordination with specialty pharmacy, and practical tools to help patients stay on therapy over the long term Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Danielle Roman, PharmD, BCOP Manager, Oncology Clinical Pharmacy Services Oncology Clinical Pharmacy Specialist Allegheny Health Network Pittsburgh, Pennsylvania Jordan Hill, PharmD, BCOP Clinical Pharmacy Specialist, Breast Oncology West Virginia University Cancer Institute Morgantown, West Virginia Link to full program: https://bit.ly/4cIYca6 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions	13 Apr 2026	00:33:13
In this episode, Dr Matthew Gubens and Dr Helena Yu discuss the evolving role of TROP2-directed therapies in non-small-cell lung cancer, with a focus on how antibody–drug conjugates (ADCs) fit into current treatment strategies, including The mechanism of action and clinical trial outcomes of TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan Use of these therapies in EGFR-mutant disease and how they fit into a changing treatment landscape Practical advice on associated adverse events and additional considerations, A look at future directions on the horizon, such as first-line studies and predictive biomarkers Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Matthew Gubens, MD, MS, FASCO Medical Director, Thoracic Medical Oncology University of California, San Francisco San Francisco, California Helena Yu, MD Professor of Medicine Thoracic Oncology Service Memorial Sloan Kettering Cancer Center New York, New York Link to full program: https://bit.ly/41vAnfH Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Emerging Therapies for Patients With HER2+ Gastroesophageal Adenocarcinoma and Biliary Tract Cancer	13 Apr 2026	00:39:12
In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the individualized care of patients with HER2-positive gastroesophageal adenocarcinoma and biliary tract cancer, including: A brief overview of BTC and GEA Notable findings from a recent survey of healthcare professionals on BTC and GEA Case studies on recommended management of patients with BTC or GEA Emerging datasets of HER2-directed therapies in BTC and GEA affecting clinical practice Challenges faced by healthcare professionals in the management of patients with BTC and/or GEA Key ongoing trials of HER2-directed therapies in BTC and GEA Presenters: Amit Mahipal, MD, MPH Chief, GI Medical Oncology Program Professor of Medicine Ruth and Goodman Endowed Chair in GI Oncology H Seidman Cancer Center and Case Western Reserve University Cleveland, Ohio Shubham Pant, MD Professor Department of Gastrointestinal Medical Oncology Department of Investigational Cancer Therapeutics, Division of Cancer Medicine MD Anderson Cancer Center Houston, Texas Link to full program: https://bit.ly/4ckcBrZ Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC	26 Mar 2026	00:19:16
In this podcast episode, Aditya Bardia, MD, MPH, FASCO, and Ruta Rao, MD, discuss ADCs for HER2-negative/ultralow/low metastatic breast cancer, including: Classifying HER2 expression in MBC today (HER2 negative/ultralow/low/positive) and why this is important ADCs for HER2-negative/ultralow/low MBC Patient communication: best practices in discussing treatment goals and potential AEs Presenters: Aditya Bardia, MD, MPH, FASCO Professor of Medicine Geffen School of Medicine University of California Los Angeles, California Ruta Rao, MD Medical Director, Rush University Cancer Center Professor of Medicine Rush University Medical Center Chicago, Illinois Content based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc. Link to full program: https://bit.ly/47JLtBt Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Colorectal Cancer	25 Mar 2026	00:33:23
Advanced practice providers discuss biomarker testing in patients with colorectal cancer. Listen in to learn from Ann Marie Siney, RN, MSN, ANP-BC, and Kathleen Boyle, DScPAS, PA-C, about familial cancer syndromes associated with colorectal cancer and key biomarker testing often used in patients with colorectal cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker for all patients. Presenters: Ann Marie Siney, RN, MSN, ANP-BC Division of Hematology/Oncology UCLA Health Santa Monica, California Kathleen Boyle, DScPAS, PA-C Gastrointestinal Cancer Center Dana-Farber Cancer Institute Boston, Massachusetts Link to full program: https://bit.ly/4spkxiC Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Prostate Cancer	25 Mar 2026	00:22:19
Listen to this audio podcast covering biomarker testing in patients with prostate cancer. Learn from Sara Traverso, MMS, PA-C, and Brenda Martone, MSN, ANP-BC, AOCNP, about when to conduct germline and somatic genetic testing in patients with prostate cancer, discussing testing with patients and their caregivers, recognizing actionable biomarkers, and improving APP confidence in the application of biomarker testing results to practice. Presenters: Sara Traverso, MMS, PA-C Physician Assistant Northwestern Medicine Robert H. Lurie Comprehensive Cancer Center Genitourinary Oncology Chicago, Illinois Brenda Martone, MSN, ANP-BC, AOCNP Nurse Practitioner Northwestern Medicine Chicago, Illinois Link to full program: https://bit.ly/3PB4ZJR Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Bladder Cancer Breakthroughs: New NMIBC Therapies and EV + Pembrolizumab Updates From ASCO GU 2026	23 Mar 2026	00:18:57
In this episode, Sam S. Chang, MD, MBA, and Matthew D. Galsky, MD, discuss the rapidly evolving treatment landscape in bladder cancer, highlighting new therapeutic options, emerging clinical trial data, including the latest results presented at ASCO GU 2026, and the growing role of biomarkers and multidisciplinary care, including: New treatment options for BCG-unresponsive non–muscle-invasive bladder cancer Intravesical therapies such as nadofaragene and N-803 The role of ctDNA in measurable residual disease detection Presenters: Sam S. Chang, MD, MBA Patricia and Rodes Hart Chair of Urologic Surgery Chief Surgical Officer Vanderbilt Ingram Cancer Center Nashville, Tennessee Matthew D. Galsky, MD Lillian and Howard Stratton Professor of Medicine Icahn School of Medicine at Mount Sinai Director, Genitourinary Medical Oncology Co-Leader, Cancer Clinical Investigation Program Associate Director for Translational Research Tisch Cancer Institute New York, New York Link to full program: https://bit.ly/479RgQn Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization	20 Mar 2026	00:25:11
In this episode, oncology pharmacists Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, explore and challenge common assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, offering insights on patient selection, trial nuances, toxicity management, and real-world decision-making. Presenters: Rodney Hunter, PharmD, BCOP Director of Clinical Services Memorial Hermann Texas Medical Center Clinical Pharmacy Specialist University of Texas Health Memorial Hermann Cancer Center Professor Texas Southern University College of Pharmacy and Health Sciences Clinical Adjunct Professor McGovern Medical School Houston, Texas Julia L. Ziegengeist, PharmD, BCOP Clinical Pharmacist Specialist, Breast Medical Oncology Levine Cancer, Atrium Health Charlotte, North Carolina Link to full program: https://bit.ly/46SPGlU Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL	11 Mar 2026	00:30:24
In this episode, Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discuss how recently presented data from ASH 2025 are shaping real-world treatment decisions for patients with relapsed/refractory chronic lymphocytic leukemia, including: How covalent and noncovalent BTK inhibitors are currently used in the United States, Brazil, and Europe Practical sequencing decisions after disease progression Emerging BTK degradersas a promising option for heavily pretreated patients Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Matthew S. Davids, MD, MMSc Associate Professor of Medicine Harvard Medical School Leader, Lymphoma Program Dana-Farber/Harvard Cancer Center Director of Clinical Research, Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts Nelson Hamerschlak, MD, PhD Head of the Department of Hematology, BMT and Clinical Cell Therapy Einstein Hospital Israelita Sao Paulo, Brazil Stephen Stilgenbauer, MD Medical Director, Comprehensive Cancer Center Ulm (CCCU) Head, Early Clinical Trials Unit (ECTU) Head, Division of CLL Department of Internal Medicine III Comprehensive Cancer Center Ulm (CCCU) University of Medical Center Ulm Ulm, Germany Link to the full program: https://bit.ly/4rsZlqF Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast	09 Mar 2026	00:37:14
Listen to learn from Sara M. Tolaney, MD, MPH, and Virginia Kaklamani, MD, DSc, about new clinical trial data and updates informing the care of patients with early breast cancer and locally advanced/metastatic breast cancer that were presented at the 2025 San Antonio Breast Cancer Symposium. Presenters: Sara M. Tolaney, MD, MPH Chief, Division of Breast Oncology Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Virginia Kaklamani, MD, DSc Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment A.B. Alexander Distinguished Chair in Oncology Leader, Breast Oncology Program UT Health San Antonio MD Anderson Cancer Center San Antonio, Texas Link to full program: https://bit.ly/46Qv9OK Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions	09 Mar 2026	00:16:44
In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including: Clinical outcomes and limitations of first-generation KRAS G12C inhibitors Key unmet needs, including primary and acquired resistance Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and immunotherapy Presenters: Luis Paz-Ares, MD, PhD Head of Medical Oncology Department Hospital Universitario 12 de Octubre Associate Professor, Universidad Complutense de Madrid Madrid, Spain Christine Bestvina, MD Associate Professor University of Chicago Medicine Division of Medicine Section of Hematology/Oncology University of Chicago Medicine Chicago, Illinois Link to full program: https://bit.ly/4rhoUuN Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies	27 Feb 2026	00:38:32
In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including: CD19-directed CAR T-cell therapies Next-generation CD19 bispecific antibodies The evolving role of allogeneic transplant Presenters: Ibrahim Aldoss, MD Associate Professor Division of Leukemia Department of Hematology/HCT City of Hope National Medical Center Duarte, California Bijal Shah, MD, MS Senior Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, Florida Link to full program: https://bit.ly/4cRjiUi Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Experts Discuss Novel RAS-Targeted Therapy for Pancreatic Cancer	23 Feb 2026	00:22:26
In this podcast episode, Nilofer Azad, MD, FASCO, and Zev A. Wainberg, MD, discuss novel RAS-targeted therapies for pancreatic cancer, including the following: Optimal KRAS mutation testing Emerging multiselective RAS inhibitors Combination strategies Presenters: Nilofer Azad, MD, FASCO Professor of Oncology Associate Director of Clinical Research Sidney Kimmel Cancer Center at Johns Hopkins University Co-Leader, Developmental Therapeutics Clinical Trials Group Baltimore, Maryland Zev A. Wainberg, MD Professor of Medicine and Surgery Co-Director, GI Oncology Program UCLA School of Medicine Los Angeles, California Content based on an online CME program supported by an educational grant from Revolution Medicines, Inc. Link to full program: https://bit.ly/4avdRZK Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Advanced Practice Professionals Discuss Biomarker Testing in Patients With Solid Tumors: Lung Cancer	20 Feb 2026	00:47:50
Advanced practice providers discuss biomarker testing in patients with lung cancer. Listen in to learn from Beth Sandy, MSN, CRNP,FAPO, and Denise Rouse, MS, PA-C, about key biomarker testing in patients with lung cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker testing in patients with lung cancer. Presenters: Beth Sandy, MSN, CRNP, FAPO Thoracic Oncology Nurse Practitioner Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania Denise Rouse, MS, PA-C Physician Assistant Thoracic Medical Oncology Department of Medicine, Section of Hematology/Oncology The University of Chicago Medicine & Biological Sciences Chicago, Illinois Link to full program: https://bit.ly/4rt1OCl Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Individualized Hemophilia Care With Hemostatic Rebalancing Therapies	30 Jan 2026	00:29:19
In this podcast episode, experts Angela Weyand and Guy Young discuss their experience using hemostatic rebalancing agents for prophylaxis in patients diagnosed with hemophilia. Three rebalancing agents have now been approved, including concizumab, fitusiran, and marstacimab. These new rebalancing agents target the body's natural anticoagulants and provide individualized, convenient options for patients older than 12 years of age.This podcast explores similarities and differences between the rebalancing agents, such as dosing, necessary lab testing, and safety profiles, that are important to discuss with patients and their caregivers. Presenters: Angela Weyand, MD Associate Professor, Pediatric Hematology Oncology Co-Director, Combined Hematology/Gynecology Program Pediatric Medical Director, Hemophilia Treatment Center University of Michigan Medical School Ann Arbor, Michigan Guy Young, MD Director, Hemostasis and Thrombosis Center Director, Clinical Coagulation Laboratory Cancer and Blood Disease Institute Children's Hospital Los Angeles Professor of Pediatrics Division of Hematology/Oncology Department of Pediatrics University of Southern California Keck School of Medicine Los Angeles, California Get access to all of our new podcasts by subscribing to the CCO Neuroscience Podcast on Apple Podcasts, YouTube Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Experts Offer Guidance on Shared Decision-making in the Management of Patients With PV/ET	21 Jan 2026	00:31:02
In this episode, hear Joan How, MD and Pankit Vachhani, MD share their insights on the importance of shared decision-making (SDM) for patients with polycythemia vera (PV) or essential thrombocythemia (ET) including: Personal insights and examples of the process of SDM with patients with PV or ET How nuances of managing PV/ET influence SDM Individualizing the process of SDM Barriers to effective SDM Educational resources for patients with PV, ET, or MPNs Working with a team to incorporate SDM into clinical practice Program faculty: Joan How, MD Scientific and Medical Consultant Clinical Chief of Hematology Brigham and Women's Faulkner Hospital Associate Physician Brigham and Women's Hospital Assistant Professor in Medicine Harvard Medical School Boston, Massachusetts Pankit Vachhani, MD Associate Professor of Medicine Division of Hematology and Oncology University of Alabama at Birmingham O’Neal Comprehensive Cancer Center at the UAB Birmingham, Alabama Link to obtain CME/CE credit: https://bit.ly/3ZtxWJm Link to program page: https://bit.ly/3YQKlHb Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Experts Discuss CELMoD Agents for Treating Multiple Myeloma	30 Dec 2025	00:17:30
In this podcast episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including: Combination strategies Adverse event management Where CELMoD agents may best fit within current and future treatment strategies Presenters: Jesus Berdeja, MD Director of Multiple Myeloma Research Greco-Hainsworth Centers for Research Tennessee Oncology Nashville, Tennessee Amrita Krishnan, MD, FACP Director, Judy and Bernard Center for Myeloma, City of Hope Nason Hollingsworth Family Chair Myeloma Executive Director, Hematology, City of Hope Orange County Professor Hematology/HCT Irvine, California Niels van de Donk, MD, PhD Professor of Hematology Department of Hematology Amsterdam UMC, Location VUmc Amsterdam, Netherlands Content based on an online CME program supported by an educational grant from Bristol Myers Squibb. Link to full program: https://bit.ly/4qvRwQM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

About Methodology Contact Support me Privacy Policy Legal Notice